IRCT20210530051440N1 IRCT 2021-06-27 Zanjan University of Medical Sciences Efficacy of Edaravone with Thrombolysis in Acute Ischemic Stroke E.T.I.S The Study of the Efficacy of Edaravone in Combination with Thrombolysis in Acute Ischemic Stroke Patients: A randomized controlled clinical trial 2021-06-22 anticipated 244 Complete https://irct.ir/trial/56649 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be allocated randomly into 2 groups by randomized block design methods with block size equal to four, using S.A.S. and Procplan software according to random numbers, Blinding description: Blinding process will be done for 3 groups: those who choose patients for the study, those who measure the parameters and follow up the patients and those who supervise the study process. The company supplying Edaravone, with assign codes for drug and placebo vials which cannot be separated by centers. All executors and colleagues will be kept blind till end of the study and decoding process will be carried out only by a statistics analyst, at the end of study. 3 Acute Ischemic Stroke. Intervention 1: Intervention group: Case group consists of patients receiving Alteplase within 4.5 hours of onset of manifestations and dose of 0.6 to 0.9 mg/kg in combination with Edaravone within 1 to 24 hours of admission (after receiving Creatinine result) and dose of 60 mg every 12 hours (40 ml of drug in 160 ml of saline infusion in 1 hour), continued for five days. Intervention 2: Control group: Control group consists of patients receiving Alteplase within 4.5 hours of onset of manifestations and dose of 0.6 to 0.9 mg/kg in with 40ml of placebo in 160 ml of saline, every 12 hours for five days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Publication of data, needs agreement of all sponsors